Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb 15;50(4):574-84.
doi: 10.1086/650004.

Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care

Justin S Routman  1 , James H Willig, Andrew O Westfall, Sarah R Abroms, Mohit Varshney, Sunil Adusumilli, Jeroan J Allison, Karen G Savage, Michael S Saag, Michael J Mugavero
Affiliations

Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care

Justin S Routman et al. Clin Infect Dis. .

Abstract

Background: The applicability of clinical trial findings (efficacy) to the routine care setting (effectiveness) may be limited because of study eligibility criteria and volunteer bias. Although well-chronicled in many conditions, the efficacy versus effectiveness of antiretroviral therapy (ART) remains understudied.

Methods: A retrospective study of the University of Alabama at Birmingham 1917 Clinic Cohort evaluated ART-naive patients who started ART from 1 January 2000 through 31 December 2006. Patients received ART through clinical trials or routine care. Multivariable logistic and linear regression models were fit to evaluate factors associated with virological failure (virological failure was defined as a viral load >50 copies/mL) and change from baseline CD4+ cell count 6 and 12 months after ART initiation. Sensitivity analyses evaluated the impact of missing data on outcomes.

Results: Among 570 patients starting ART during the study period, 121 (21%) enrolled in clinical trials, and 449 (79%) received ART via routine care. ART receipt through routine care was not associated with viral failure at either 6 months (odds ratio [OR], 1.00; 95% confidence interval [CI], 0.54-1.86) or 12 months (OR, 1.56; 95% CI, 0.80-3.05) in primary analyses. No statistically significant differences in CD4+ cell count responses at 6 and 12 months were observed.

Conclusions: Although marked differences in efficacy versus effectiveness have been observed in the therapeutic outcomes of other conditions, our analyses found no evidence of such divergence among our patients who initiated antiretroviral therapy for human immunodeficiency virus infection.

PubMed Disclaimer

References

    1. Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine levels of evidence. Oxford: Centre for Evidence-based Medicine; Mar2009. [accessed July 5, 2009]. http://www.cebm.net/levels_of_evidence.asp.
    1. Bahit MC, Cannon CP, Antman EM, et al. Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. Am Heart J. 2003 Jan;145(1):109–17. - PubMed
    1. Eg Hansen AB, Gerstoft J, Kirk O, et al. Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial. J Clin Epidemiol. 2008 Jan;61(1):87–94. - PubMed
    1. Hordijk-Trion M, Lenzen M, Wijns W, et al. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J. 2006 Mar;27(6):671–8. - PubMed
    1. Steg PG, Lopez-Sendon J, Lopez de Sa E, et al. External validity of clinical trials in acute myocardial infarction. Archives of internal medicine. 2007 Jan 8;167(1):68–73. - PubMed

Publication types